Nivolumab and berahyaluronidase alfa-pmph ,Opdivo SC ,Opdivo Subcutaneous Injection ,Opdivo Qvantig ,BMS-986251 ,Subcutaneous PD-1 inhibitor ,Combination Product (901 and 932)
Nivolumab and berahyaluronidase alfa-pmph ,Opdivo SC ,Opdivo Subcutaneous Injection ,Opdivo Qvantig ,BMS-986251 ,Subcutaneous PD-1 inhibitor ,Combination Product (901 and 932)
Trade Name
Opdivo Qvantig®
Target
N/A
Molecular Type
Combination Product (901 And 932)
Sales In 2025 (Millions Of USD)
N/A
Product Description
Detailed Specifications & Features
Trade Name : Opdivo Qvantig®
Target : N/A
Molecular Type : Combination Product (901 and 932)
Sales in 2025 (Millions of USD) : N/A
All detailed product information shall be subject to the issued final COA.
Should you need further in-depth documentation for this item, kindly get in touch with us.
